keyword
MENU ▼
Read by QxMD icon Read
search

Prednisone bone

keyword
https://www.readbyqxmd.com/read/29326030/patient-reported-outcomes-following-abiraterone-acetate-plus-prednisone-added-to-androgen-deprivation-therapy-in-patients-with-newly-diagnosed-metastatic-castration-naive-prostate-cancer-latitude-an-international-randomised-phase-3-trial
#1
Kim N Chi, Andrew Protheroe, Alfredo Rodríguez-Antolín, Gaetano Facchini, Henrik Suttman, Nobuaki Matsubara, Zhangqun Ye, Bhumsuk Keam, Ronaldo Damião, Tracy Li, Kelly McQuarrie, Bin Jia, Peter De Porre, Jason Martin, Mary B Todd, Karim Fizazi
BACKGROUND: In the LATITUDE trial, addition of abiraterone acetate plus prednisone to androgen deprivation therapy (ADT) improved overall survival compared with placebos plus ADT in patients with newly diagnosed, high-risk, metastatic castration-naive prostate cancer. Understanding the effects of treatments on patient-reported outcomes (PROs) and health-related quality of life (HRQOL) is important for treatment decisions; therefore we aimed to analyse the effects of ADT plus abiraterone acetate and prednisone versus ADT plus placebos on PROs and HRQOL in patients in the LATITUDE study...
January 8, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/29323335/tanshinol-alleviates-impaired-bone-formation-by-inhibiting-adipogenesis-via-klf15-ppar%C3%AE-2-signaling-in-gio-rats
#2
Ya-Jun Yang, Zhu Zhu, Dong-Tao Wang, Xin-le Zhang, Yu-Yu Liu, Wen-Xiu Lai, Yu-Lin Mo, Jin Li, Yan-Long Liang, Zhuo-Qing Hu, Yong-Jie Yu, Liao Cui
Glucocorticoid (GC)-induced osteoporosis (GIO) is characterized by impaired bone formation, which can be alleviated by tanshinol, an aqueous polyphenol isolated from Salvia miltiorrhiza Bunge. In this study we investigated the molecular mechanisms underlying GC-induced modulation of osteogenesis as well as the possibility of using tanshinol to interfere with GIO. Female SD rats aged 4 months were orally administered distilled water (Con), prednisone (GC, 5 mg·kg-1·d-1), GC plus tanshinol (Tan, 16 mg·kg-1·d-1) or GC plus resveratrol (Res, 5 mg·kg-1·d-1) for 14 weeks...
January 11, 2018: Acta Pharmacologica Sinica
https://www.readbyqxmd.com/read/29241166/the-clinical-efficacy-of-radium-223-for-bone-metastasis-in-patients-with-castration-resistant-prostate-cancer-an-italian-clinical-experience
#3
Rossella De Luca, Renato Patrizio Costa, Vincenzo Tripoli, Alessandra Murabito, Giuseppe Cicero
BACKGROUND/AIM: Prostate cancer frequently causes bone metastases and skeletal events that impair quality of life (QoL) and survival. The alpha emitter radium-223 is a new drug that improves treatment in men with castration-resistant prostate cancer (CRPC) and bone metastases. Our aim was to evaluate the effectiveness of radium-223. SUBJECTS AND METHODS: In this retrospective study we enrolled 48 subjects. Pain reduction, alkaline phosphatase (ALP), time to first symptomatic skeletal event, and QoL were the variables we evaluated...
December 15, 2017: Oncology
https://www.readbyqxmd.com/read/29239119/a-retrospective-review-of-acute-myeloid-leukaemia-in-35-dogs-diagnosed-by-a-combination-of-morphologic-findings-flow-cytometric-immunophenotyping-and-cytochemical-staining-results-2007-2015
#4
L L Davis, K R Hume, T Stokol
Acute myeloid leukaemia (AML) is an uncommon, rapidly progressive neoplasm in dogs. The aim of this retrospective study was to characterize the clinical presentation, haematologic findings, diagnostic imaging results, treatment and survival time of a contemporary cohort of dogs with AML. Diagnosis was based on >20% blasts in bone marrow or blood identified as myeloid based on morphologic findings, flow cytometric immunophenotyping and cytochemical staining. Medical records of 35 dogs diagnosed with AML from 2007 to 2015 were included...
December 14, 2017: Veterinary and Comparative Oncology
https://www.readbyqxmd.com/read/29228594/bone-strengthening-pill-bsp-promotes-bone-cell-and-chondrocyte-repair-and-the-clinical-and-experimental-study-of-bsp-in-the-treatment-of-osteonecrosis-of-the-femoral-head
#5
Zheng Li, Lulin Wang, Jin Wei, Liguo Zhu, Xisheng Weng, Jin Jin, Hong Xiao, Jun Zhang, Heming Wang, Guantong Shi, Lingpeng Pei, Fangde Zou, Wanqiang Zhang, Tianzun Tao, Xin Dong
About 1 in 3 people suffer from bone and joint disease, which is a disease of bone and cartilage cells. Osteonecrosis of the femoral head (ONFH) is a typical example of bone and joint disease involving bone cell necrosis. Osteonecrosis of the femoral head leads to the occurrence of premature osteoarthritis of the hip and collapse of the cartilage cells, and there is currently no effective drug treatment available. In order to study the effects of "bone-strengthening pill" (BSP) on the repair of bone and cartilage cells, we investigated the potential effects of the herbal mixture BSP in an animal model of avascular necrosis of the femoral head and in patients...
November 14, 2017: Oncotarget
https://www.readbyqxmd.com/read/29196208/eradicate-a-prospective-evaluation-combining-radium-223-dichloride-and-abiraterone-acetate-plus-prednisone-in-patients-with-castration-resistant-prostate-cancer
#6
Neal D Shore, Ronald F Tutrone, Neil F Mariados, Luke T Nordquist, Bryan A Mehlhaff, Karyn J Steere, Stacey S Harrelson
BACKGROUND: Multiple castration-resistant prostate cancer (CRPC) therapies are approved by the United States Food and Drug Administration. Radium-223 dichloride (Ra-223) with abiraterone acetate plus prednisone have different mechanisms of action and distinct off-target side-effect profiles. We prospectively investigated their combined safety, tolerability, and patient-reported outcome measures. PATIENTS AND METHODS: eRADicAte, an investigator-initiated, phase II trial, studied 31 patients with metastatic CRPC, from 5 United States uro-oncology research sites...
November 7, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/29190607/effect-of-paricalcitol-on-bone-density-after-kidney-transplantation-analysis-of-2-transplant-centers
#7
Zuzana Žilinská, Ivana Dedinská, Ján Breza, Ludovít Laca
INTRODUCTION: The Kidney Disease: Improving Global Outcomes Clinical Practice Guidelines on the management of bone disease in patients with chronic kidney disease recommend periodic measurement of serum calcium, phosphorus, vitamin D, and parathyroid hormone levels after kidney transplantation, with the frequencies that will vary according to the severity of bone disease and graft function. Paricalcitol, a selective vitamin D receptor activator, is indicated in the prevention and treatment of secondary hyperparathyroidism...
November 2017: Iranian Journal of Kidney Diseases
https://www.readbyqxmd.com/read/29190181/identifying-opportunities-to-bridge-disparity-gaps-in-curing-childhood-cancer-in-malawi-malignancies-with-excellent-curative-potential-account-for-the-majority-of-diagnoses
#8
Nader Kim El-Mallawany, Peter Wasswa, Idah Mtete, Mercy Mutai, Christopher C Stanley, Mary Mtunda, Mary Chasela, Atupele Mpasa, Stella Wachepa, William Kamiyango, Jimmy Villiera, Peter N Kazembe, Parth S Mehta
The majority of African children with cancer die without access to resources. We describe efforts to build a public treatment program with curative intent for childhood cancer in Lilongwe, Malawi despite severe limitations in diagnostic and therapeutic resources. We retrospectively analyzed a cohort of childhood cancer patients at Kamuzu Central Hospital from 12/2011-6/2013. Consistently available chemotherapeutic agents were limited to cyclophosphamide, vincristine, doxorubicin, bleomycin, methotrexate, and prednisone...
November 30, 2017: Pediatric Hematology and Oncology
https://www.readbyqxmd.com/read/29187931/-diagnostic-and-evolutionary-profile-of-multiple-myeloma-in-senegal-monocentric-study-conducted-from-2005-to-2016
#9
Seynabou Fall, Fatma Dieng, Coumba Diouf, Boundia Djiba, Awa Cheikh Ndao, Fatou Samba Diago Ndiaye
Introduction: Accessibility to innovative multiple myeloma therapies is limited in sub-Saharan Africa. This study aimed to describe the diagnostic and evolutionary features observed during treatment of our patients with myeloma. Methods: We conducted a retrospective, descriptive, analytical study (2005 - 2016) of patients with myeloma included in the study based on International Myeloma Working Group (IMWG) Criteria (2003,2014) at the Hopital Aristide Le Dantec (Senegal)...
2017: Pan African Medical Journal
https://www.readbyqxmd.com/read/29180875/effective-treatment-of-low-dose-decitabine-in-myelodysplastic-syndrome-myeloproliferative-neoplasms
#10
Xingnong Ye, Dan Chen, Yan Zheng, Xiaoqiong Zhu, Junkai Fu, Jian Huang
Objective: Primary myelofibrosis (PMF) is one of the Philadelphia negative myeloproliferative neoplasms (MPN). The main clinical features are obvious physical symptoms and symptomatic splenomegaly. It may be converse to leukemia and has a shortened life expectancy. Nowadays, the therapy for PMF is aimed at maintaining comfort and there is no curative treatment. PMF with myelodysplastic syndrome (MDS), called MDS/MPN-u, is rare and the treatment is complex. In this study, we want to discuss an effective treatment for MDS/MPN via a case report and literature review...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/29177266/atypical-epstein-barr-virus-associated-hemophagocytic-lymphohistiocytosis-simulating-lymphadenitis-on-18f-fdg-pet-ct-and-its-differential-diagnosis
#11
Jing Lu, Qingquan Fang, Chao Ma, Fu Su, Guoqiang Chen, Meiling Huang, Weixing Wang, Xinhui Su
Diagnosis of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis (EBV-HLH) is challenging as its clinical presentation is atypical. Here we present a case of atypical EBV-HLH simulating lymphadenitis on fluorrine-18-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT), with a view to consider this kind of EBV-HLH as a possible differential diagnosis in lymphadenitis. A 68 years old male who had episodic fever accompanied by weight loss and weakness for two weeks was studied...
November 27, 2017: Hellenic Journal of Nuclear Medicine
https://www.readbyqxmd.com/read/29124434/effect-of-prednisone-treatment-for-30-and-90%C3%A2-days-on-bone-metabolism-in-collagen-induced-arthritis-cia-rats
#12
Xinle Zhang, Xuna Wu, Yalin Min, Jiaqi Lu, Xuemei Zhang, Wenshuang Chen, Liyi Zou, Xiaohua Lv, Liao Cui, Bilian Xu
Glucocorticoids (GCs) are often prescribed to treat rheumatoid arthritis (RA) in the long term, but there is still controversy in the administration of GCs, mainly because of the adverse reactions such as osteoporosis. Numerous studies have demonstrated that osteoporosis could be induced by GCs in normal rats. However, few experiments have focused on whether osteoporosis could be induced or aggravated by GCs in collagen induced arthritis (CIA) rats. We have investigated bone changes in CIA rats treated with prednisone at 4...
November 9, 2017: Journal of Bone and Mineral Metabolism
https://www.readbyqxmd.com/read/29115514/polygonum-multiflorm-alleviates-glucocorticoid%C3%A2-induced-osteoporosis-and-wnt-signaling-pathway
#13
Manru Zhou, Jingkai Wu, Yongjie Yu, Yajun Yang, Jin Li, Liao Cui, Weimin Yao, Yuyu Liu
It is known that long‑term excessive administration of glucocorticoid (GC) results in osteoporosis. The present study aimed to evaluate the protective effects of Polygonum multiflorm (PM) on the bone tissue of rats with GC‑induced osteoporosis (GIO). A total of 90 6‑month‑old female Sprague Dawley rats (weight range, 190‑210 g) were randomly divided into nine groups: Control (normal saline); prednisone (GC; 6 mg·kg‑1·d‑1; Model); GC plus PMR30 (the 30% ethanol eluent fraction of PM) (H) (400 mg·kg‑1·d‑1); GC plus PMR30 (M) (200 mg·kg‑1·d‑1); GC plus PMR30 (L) (100 mg·kg‑1·d‑1); GC plus PMRF (fat‑soluble fraction of PM) (H) (400 mg·kg‑1·d‑1); GC plus PMRF (M) (200 mg·kg‑1·d‑1); GC plus PMRF (L) (100 mg·kg‑1·d‑1); GC plus calcitriol (CAL; 0...
January 2018: Molecular Medicine Reports
https://www.readbyqxmd.com/read/29102858/weekly-cabazitaxel-plus-prednisone-is-effective-and-less-toxic-for-unfit-metastatic-castration-resistant-prostate-cancer-phase-ii-spanish-oncology-genitourinary-group-sogug-trial
#14
Miguel Ángel Climent, Begoña Pérez-Valderrama, Begoña Mellado, Eva María Fernández Parra, Ovidio Fernández Calvo, María Ochoa de Olza, Laura Muinelo Romay, Urbano Anido, Montserrat Domenech, Susana Hernando Polo, José Ángel Arranz Arija, Cristina Caballero, María José Juan Fita, Daniel Castellano
AIM: Cabazitaxel (CBZ), a novel tubulin-binding taxane, improves overall survival in metastatic castration-resistant prostate cancer (mCRPC) that progresses during or after docetaxel treatment. We have designed a phase II study to evaluate the efficacy and safety of CBZ as a weekly schedule for 'unfit' mCRPC patients after docetaxel failure. METHODS: In this single arm phase II study. CBZ was weekly administered in 1-hour infusion on days 1, 8, 15 and 22, every 5 weeks at 10 mg/m(2) to eligible 'unfit' patients; oral prednisone (5 mg) was administered twice a day...
November 2, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/29091890/the-effect-of-clinically-relevant-doses-of-immunosuppressive-drugs-on-human-mesenchymal-stem-cells
#15
Eliska Javorkova, Julie Vackova, Michaela Hajkova, Barbora Hermankova, Alena Zajicova, Vladimir Holan, Magdalena Krulova
Immunosuppressive drugs are used to suppress graft rejection after transplantation and for the treatment of various diseases. The main limitations of their use in clinical settings are severe side effects, therefore alternative approaches are desirable. In this respect, mesenchymal stem cells (MSCs) possess a regenerative and immunomodulatory capacity that has generated considerable interest for their use in cell-based therapy. Currently, MSCs are tested in many clinical trials, including the treatment of diseases which require simultaneous immunosuppressive treatment...
October 27, 2017: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
https://www.readbyqxmd.com/read/29069303/a-prospective-genome-wide-study-of-prostate-cancer-metastases-reveals-association-of-wnt-pathway-activation-and-increased-cell-cycle-proliferation-with-primary-resistance-to-abiraterone-acetate-prednisone
#16
L Wang, S M Dehm, D W Hillman, H Sicotte, W Tan, M Gormley, V Bhargava, R Jimenez, F Xie, P Yin, S Qin, F Quevedo, B A Costello, H C Pitot, T Ho, A H Bryce, Z Ye, Y Li, P Eiken, P T Vedell, P Barman, B P McMenomy, T D Atwell, R E Carlson, M Ellingson, B Eckloff, R Qin, F Ou, S N Hart, H Huang, J Jen, E D Wieben, K R Kalari, R M Weinshilboum, L Wang, M Kohli
Background: Genomic aberrations have been identified in metastatic castration-resistant prostate cancer (mCRPC), but molecular predictors of resistance to abiraterone acetate/prednisone (AA/P) treatment are not known. Patients and Methods: In a prospective clinical trial, mCRPC patients underwent whole exome sequencing (n = 82) and RNA-sequencing (n = 75) of metastatic biopsies before initiating AA/P with the objective of identifying genomic alterations associated with resistance to AA/P...
October 23, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29043235/platelet-to-lymphocyte-ratio-plr-retains-independent-prognostic-significance-in-advanced-stage-marginal-zone-lymphoma-patients-treated-with-rituximab-cyclophosphamide-vincristine-and-prednisone-combination-chemotherapy-r-cvp-consortium-for-improving-survival
#17
Jeongkuk Seo, Won Seog Kim, Jin Seok Kim, Seok Jin Kim, Jae Hoon Lee, Jun Shik Hong, Gyeong-Won Lee, Sung Yong Oh, Ji-Hyun Lee, Dok Hyun Yoon, Won-Sik Lee, Hyo Jung Kim, Jae-Yong Kwak, Hye Jin Kang, Jae-Cheol Jo, Yong Park, Ho Sup Lee, Hyo-Jin Kim, Cheolwon Suh
BACKGROUND: Rituximab plus cyclophosphamide, vincristine, and prednisone (R-CVP) is one of the effective chemotherapeutic regimens for patients with advanced stage marginal zone lymphoma (MZL). However, prognostic factors that affect the outcome of treatment for MZL are not well understood. METHODS: Between August 2006 and June 2013, patients with newly diagnosed stage III and IV MZL treated with R-CVP as a first-line therapy from 15 institutions were retrospectively analyzed...
September 2017: Blood Research
https://www.readbyqxmd.com/read/29033099/custirsen-ogx-011-combined-with-cabazitaxel-and-prednisone-versus-cabazitaxel-and-prednisone-alone-in-patients-with-metastatic-castration-resistant-prostate-cancer-previously-treated-with-docetaxel-affinity-a-randomised-open-label-international-phase-3-trial
#18
Tomasz M Beer, Sebastien J Hotte, Fred Saad, Boris Alekseev, Vsevolod Matveev, Aude Fléchon, Gwenaelle Gravis, Florence Joly, Kim N Chi, Zafar Malik, Brent Blumenstein, Patricia S Stewart, Cindy A Jacobs, Karim Fizazi
BACKGROUND: Docetaxel and cabazitaxel improve overall survival compared with mitoxantrone in patients with metastatic castration-resistant prostate cancer. Custirsen (OGX011) is a second generation highly specific antisense oligonucleotide that inhibits the production of clusterin, an antiapoptotic protein that is upregulated in response to chemotherapy and that confers treatment resistance. We aimed to assess whether custirsen in combination with cabazitaxel and prednisone increases overall survival in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel...
October 9, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28962180/preventive-effects-of-polygonum-multiflorum-on-glucocorticoid-induced-osteoporosis-in-rats
#19
Manru Zhou, Jin Li, Jingkai Wu, Yajun Yang, Xiaobing Zeng, Xiaohua Lv, Liao Cui, Weimin Yao, Yuyu Liu
In Traditional Chinese Medicine, Polygonum multiflorum (PM) is known for its anti-aging properties. A previous study by our group showed that extracts of PM were able to prevent and treat bone loss in vivo, and the active components emodin and 2,3,5,4,-tetrahydroxystilbene-2-O-β-glucoside (TSG) promoted the osteogenic differentiation of mesenchymal stem cells in vitro. The aim of the present study was to investigate the preventive effects of PM on glucocorticoid-induced osteoporosis (GIO) in rats. A crude extract of PM was prepared with 75% ethanol, purified and enriched using a D-101 macroresin column and elution with 30% ethanol, and the material obtained was assessed by high-performance liquid chromatography...
September 2017: Experimental and Therapeutic Medicine
https://www.readbyqxmd.com/read/28918421/macrophage-activation-syndrome-at-the-onset-of-glucocorticoid-resistant-systemic-lupus-erythematosus-a-case-report
#20
Delia Tulbă, Marius Balea, Cristian Băicuș
INTRODUCTION: Macrophage activation syndrome (MAS) is a life-threatening hyperinflammatory state mediated by uncontrolled cytokine storm and haemophagocytosis. Although rarely reported, MAS might occur in systemic lupus erythematosus (SLE), notably as an inaugural manifestation. Glucocorticoids (GCs) are the cornerstone of SLE therapy. However, in some cases high doses of GCs are required to achieve remission (i.e. glucocorticoid-resistance), leading to significant side effects. CASE REPORT: A 28-year-old Romani male was admitted to our hospital for polyarthralgia, polyserositis and fatigability...
September 16, 2017: Romanian Journal of Internal Medicine, Revue Roumaine de Médecine Interne
keyword
keyword
7843
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"